Susan G. Komen® and GE Healthcare Partner to Improve Lives and Raise Awareness of Advancements in Diagnostics and Treatment Options for Metastatic Breast Cancer
GE Healthcare, a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, are partnering for the first time to support the MBC)+Impact+Series">Susan G Komen's Metastatic Breast Cancer (MBC) Impact Series
DALLAS, Sept. 28, 2022 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, and GE Healthcare, a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, are partnering for the first time to support the MBC)+Impact+Series">Susan G Komen's Metastatic Breast Cancer (MBC) Impact Series.
Every person deserves personalized breast cancer care options. In continuing its support of Susan G. Komen and efforts to improve outcomes for the breast cancer community, GE Healthcare has made a commitment to help Komen provide critical educational programs for the MBC community.
GE Healthcare's investment will support the Susan G. Komen's MBC Impact Series to ensure that people living with MBC and their loved ones have a safe and collaborative space to gather information to help make decisions for improved physical and emotional health.
"As a leader in imaging and healthcare innovation, GE Healthcare has shown its commitment to the MBC community through its investment in groundbreaking imaging agents that highlight estrogen receptor-positive tumors in patients whose breast cancer has recurred or spread," said Victoria Wolodzko Smart, Senior Vice President of Mission at Komen. "GE Healthcare's goals are aligned with our goal to conquer aggressive and deadly breast cancers and this partnership will help us bring critically needed access to the latest information on imaging, treatments and innovations to empower MBC patients."
